tbuckley/cabot-search huggingface dataset:
Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer.
Authors: D. Weycker, J. R. Jett, F. C. Detterbeck, D. L. Miller, A. Khuu, T. C. Kennedy, P. Boyle, J. F. Robertson, G. Hamilton-Fairley, J. Edelsberg
Journal: Journal of Clinical Oncology (2010)

7030 Background: An AABT to aid in lung cancer diagnosis has been recently developed. While less sensitive than computed tomography (CT), it can detect smaller and less-advanced cancers and has greater specificity. The cost-effectiveness of AABT in this use is unknown. Methods: We developed a model depicting the consequences of screening—a single time —a hypothetical cohort of 100,000 high-risk screening-naive patients for lung cancer using CT followed by AABT if positive (CT->AABT) versus CT alone and no screening (with CT or AABT). Non-small cell lung cancer (NSCLC)—indolent and aggressive types—and small cell lung cancer (SCLC) were considered. Sensitivity and specificity of AABT (price=$300) were assumed to be 40% and 90% (data on file, Oncimmune Inc.); for CT (price=$301), were calculated to be 47% and 49% from a “prevalence screen” perspective using data from the Mayo Clinic screening study. Cancers detected with CT->AABT were assumed, on average, to be smaller and less advanced due to more aggressive work-up of patients positive on both tests. Cost-effectiveness was calculated as the ratio of the difference in expected costs (2008 USD) to the difference in life-years (LY) (and quality-adjusted life- years [QALYs]) for CT->AABT versus CT alone and no screening. Results: A total of 2,901 of the 100,000 high-risk persons would be expected to have undiagnosed aggressive NSCLC or SCLC. Of the 2,901 cases, 1,363 (true positives) would be detected with CT->AABT or CT alone and would gain 6.3 and 5.7 LYs, respectively, versus no screening; false positives would total 49,079. Cost per LY gained with CT->AABT vs no screening was $20,044, and versus CT alone, $19,293. Estimates of cost per QALY gained were similar. Conclusions: Screening high-risk patients for lung cancer using AABT as an aid to CT based on the above assumptions is likely to be cost-effective by current standards in comparison with screening with CT alone or no screening. Model outcomes (discounted) No screening CT CT- >AABT LY 1,505,557 1,509,526 1,510,392 QALY 1,303,4 17 1,305,991 1,306,651 Costs $230,946,859 $311,161,933 $327,875,140 Screening $0 $30,051,000 $43,780,230 Diagnostic $10,480,549 $51,227,441 $55,250,510 Treatment $220,466,310 $229,88 3,492 $228,844,400 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Oncimmune Oncimmune Oncimmune Ethicon Endosurgery, Inc., Synovis, Inc. Oncimmune, Policy Analysis Inc. Oncimmune
Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer
Authors: Mieke Van Hemelrijck, Hans Garmo, Lars Lindhagen, Ola Bratt, Pär Stattin, Jan Adolfsson
Journal: European Urology (2016)

Active surveillance (AS) is commonly used for men with low-risk prostate cancer (PCa). When life expectancy becomes too short for curative treatment to be beneficial, a change from AS to watchful waiting (WW) follows. Little is known about this change since it is rarely documented in medical records.To model transition from AS to WW and how this is affected by age and comorbidity among men with very low-risk PCa.National population-based healthcare registers were used for analysis.Using data on PCa characteristics, age, and comorbidity, a state transition model was created to estimate the probability of changes between predefined treatments to estimate transition from AS to WW.Our estimates indicate that 48% of men with very low-risk PCa starting AS eventually changed to WW over a life course. This proportion increased with age at time of AS initiation. Within 10 yr from start of AS, 10% of men aged 55 yr and 50% of men aged 70 yr with no comorbidity at initiation changed to WW. Our prevalence simulation suggests that the number of men on WW who were previously on AS will eventually stabilise after 30 yr. A limitation is the limited information from clinical follow-up visits (eg, repeat biopsies).We estimated that changes from AS to WW become common among men with very low-risk PCa who are elderly. This potential change to WW should be discussed with men starting on AS. Moreover, our estimates may help in planning health care resources allocated to men on AS, as the transition to WW is associated with lower demands on outpatient resources.Changes from active surveillance to watchful waiting will become more common among men with very low-risk prostate cancer. These observations suggest that patients need to be informed about this potential change before they start on active surveillance.
Refining the Patient Navigation Role in a Colorectal Cancer Screening Program: Results From an Intervention Study
Authors: Elizabeth A. Rohan, Beth Slotman, Amy DeGroff, Kerry Grace Morrissey, Jennifer Murillo, Paul Schroy
Journal: Journal of the National Comprehensive Cancer Network (2016)

Oncology patient navigators help individuals overcome barriers to increase access to cancer screening, diagnosis, and timely treatment. This study, part of a randomized intervention trial investigating the efficacy of patient navigation in increasing colonoscopy completion, examined navigators' activities to ameliorate barriers to colonoscopy screening in a medically disadvantaged population.This study was conducted from 2012 through 2014 at Boston Medical Center. We analyzed navigator service delivery and survey data collected on 420 participants who were navigated for colonoscopy screening after randomization to this intervention. Key variables under investigation included barriers to colonoscopy, activities navigators undertook to reduce barriers, time navigators spent on each activity and per contact, and patient satisfaction with navigation services. Descriptive analysis assessed how navigators spent their time and examined what aspects of patient navigation were most valued by patients.Navigators spent the most time assessing patient barriers/needs; facilitating appointment scheduling; reminding patients of appointments; educating patients about colorectal cancer, the importance of screening, and the colonoscopy preparation and procedures; and arranging transportation. Navigators spent an average of 44 minutes per patient. Patients valued the navigators, especially for providing emotional/peer support and explaining screening procedures and bowel preparation clearly.Our findings help clarify the role of the navigator in colonoscopy screening within a medically disadvantaged community. These findings may help further refine the navigator role in cancer screening and treatment programs as facilities strive to effectively and efficiently integrate navigation into their services.
Stop calling GPs gatekeepers
Authors: Arnold Zermansky
Journal: BMJ (2016)

Am I alone in regarding the description of my job as a gatekeeper to be inaccurate, condescending, and demeaning?1

Gatekeepers prevent admission. Like the sinister gatekeeper in Kafka’s parable Before the Law , who bars the traveller entry to a gate that is specifically for him. Death supervenes before he can …
Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.
Authors: Mohamad Mohty, Myriam Labopin, Jeroen JWM Janssen, Ghulam J Mufti, J. J. Cornelissen, Noel-Jean Milpied, Henrik Sengeloev, Didier Blaise, Eefke Petersen, Hakan Goker, John G. Gribben, Arnon Nagler, Vanderson Rocha
Journal: Blood (2009)
The role of staging and adjuvant chemotherapy in stage I malignant ovarian germ cell tumors (MOGTs): the MITO-9 study
Authors: G. Mangili, C. Sigismondi, D. Lorusso, G. Cormio, M. Candiani, G. Scarfone, F. Mascilini, A. Gadducci, A.M. Mosconi, P. Scollo, C. Cassani, S. Pignata, G. Ferrandina
Journal: Annals of Oncology (2016)
Transintestinal Cholesterol Transport Is Active in Mice and Humans and Controls Ezetimibe-Induced Fecal Neutral Sterol Excretion
Authors: Lily Jakulj, Theo H. van Dijk, Jan Freark de Boer, Ruud S. Kootte, Marleen Schonewille, Yared Paalvast, Theo Boer, Vincent W. Bloks, Renze Boverhof, Max Nieuwdorp, Ulrich H.W. Beuers, Erik S.G. Stroes, Albert K. Groen
Journal: Cell Metabolism (2016)
Immunogenicity and Safety of One Dose of Influenza A H1N1v 2009 Adjuvanted Vaccine for Unpreviously Treated Patients with Binet-Stage A Chronic Lymphoid Leukaemia of B-Cell Type (B-CLL): Result of a Prospective Study Conducted In 9 French Centers by the Intergroupe Français GOELAMS/GFLLC-MW
Authors: Jean-Francois Rossi, Bastien Caumes, Florence Cymbalista, Odile Launay, Anne Krivine, Vincent Levy, Pierre Feugier, Stéphane Leprêtre, Loic Ysebaert, Caroline Dartigeas, Philippe Colombat, Didier Bouscary, Tarik Kanouni, Edouard Tuaillon, Véronique Leblond
Journal: Blood (2010)
Anemia Prevalence in a Population of Over One Thousand School Children in Northeastern Mexico
Authors: Jose R Borbolla Escoboza, Patricia Argentina Ugalde, Luz Leticia Elizondo, Beatriz Eugenia Patiño, Luis M Villela, Sean P Scott, Fernando Cristobal Diaz, Yocanxochitl Perfecto, Maria Isabel Garcia, Carlos Rocha, Jina Kim
Journal: Blood (2008)
Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia with Pegasparaginase and Erwinia Asparaginase: The Impact of Expensive Chemotherapy
Authors: Wing H. Tong, Inge M. van der Sluis, Cathelijne Alleman, Raphaele RL van Litsenburg, Gertjan Kaspers, Rob Pieters, Carin A. Uyl-de Groot
Journal: Blood (2012)
London hospital trust is placed in special measures
Authors: Ingrid Torjesen
Journal: BMJ (2016)

St George’s University Hospitals NHS Foundation Trust in southwest London, responsible for one of the largest teaching hospitals in the United Kingdom, will be placed in special measures after it was rated inadequate by the Care Quality Commission.

A CQC inspection in June and July found that there had been “a marked deterioration” in the safety and quality of some of the trust’s services and in its overall governance and leadership since its …
Tetrahydrouridine Co-Administration Improves Oral Bioavailability and Dampens Inter-Individual Variability of Decitabine Pharmacokinetics In Baboons
Authors: Donald Lavelle, Kestis Vaitkus, YongHua Ling, Nicola Smith, Kenneth K. Chan, Joseph DeSimone, Yogenthiran Saunthararajah
Journal: Blood (2010)
Conversion of Alloantigen-Specific CD8+ T-Cell Anergy to T-Cell Priming through In Vivo Ligation of Glucocorticoid-Induced Tumor Necrosis Factor Receptor.
Authors: Hawk Kim, Byungsuk Kwon, Juyang Kim, Woon S. Choi, Hye J. Kim, Jae-Hee Suh, Shimon Sakaguchi
Journal: Blood (2005)
The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells
Authors: Fanny Angelot-Delettre, Arthur E. Frankel, Jen Sing Liu, Estelle Seilles, Sabeha Biichle, Bernard Drenou, Mark L. Jacobson, Thomas P. Cirrito, Arkam Yazid, Eric Deconinck, Christopher L. Brooks, Philippe Saas, Francine Garnache Ottou
Journal: Blood (2011)
Deleting an Nr4a1 Super-Enhancer Subdomain Ablates Ly6C low Monocytes while Preserving Macrophage Gene Function
Authors: Graham D. Thomas, Richard N. Hanna, Neelakatan T. Vasudevan, Anouk A. Hamers, Casey E. Romanoski, Sara McArdle, Kevin D. Ross, Amy Blatchley, Deborah Yoakum, Bruce A. Hamilton, Zbigniew Mikulski, Mukesh K. Jain, Christopher K. Glass, Catherine C. Hedrick
Journal: Immunity (2016)
Toward a Better Recognition of Clinically Impairing Grief: Response to Smid and Boelen
Authors: Stephen J. Cozza, Joscelyn E. Fisher, Christine Mauro, Jing Zhou, Claudio D. Ortiz, Natalia Skritskaya, Melanie M. Wall, Carol S. Fullerton, Robert J. Ursano, M. Katherine Shear
Journal: American Journal of Psychiatry (2016)
18F-FDG Imaging of Chronic Inflammation Associated With Promontofixation of the Uterus
Authors: Marie Meyer, Philippe Fernandez, Paolo Zanotti-Fregonara
Journal: Clinical Nuclear Medicine (2016)

A high F-FDG uptake was found in a mesh of promontofixation in a 74-year-old woman who underwent a PET/CT scan for initial staging of cervical cancer. The patient underwent a laparoscopic treatment for a prolapsed uterus 7 years before. Promontofixation can be associated with complications due to chronic inflammation. F-FDG-PET may diagnose chronic inflammation of the mesh.
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant.
Authors: Luisa Giaccone, Marcello Rotta, Bernardino Allione, Fabrizio Carnevale-Schianca, Carlo Rosanelli, Giovannino Ciccone, Marco Casini, Antonio Capaldi, Gabriele Aitoro, Paola Omedè, Silvano Battaglio, Massimo Massaia, Paolo Coser, Massimo Aglietta, Alessandro Levis, Rainer Storb, Benedetto Bruno, Mario Boccadoro
Journal: Blood (2004)
P266 Do endothelin-1 and inflammation play a role in airway obstruction in pulmonary arterial hypertension associated with congenital heart disease?: Abstract P266 Table 1
Authors: AT Low, SJ George, AB Millar, RMR Tulloh
Journal: Thorax (2015)

<h3>Introduction</h3> Airway obstruction has been demonstrated in patients with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease (CHD-APAH), but the cause is unknown. The vasoactive mediator endothelin-1 is a potent vasoconstrictor that induces smooth muscle proliferation in pulmonary arterial hypertension. Endothelin-1 also has the potential to cause bronchoconstriction when present in the airways, though this has not been demonstrated in CHD-APAH. Systemic inflammation also occurs in CHD-APAH but associated airway inflammation has not been investigated. This study investigates the relationship between inflammation, endothelin-1 and airway dysfunction in CHD-APAH patients. <h3>Methods</h3> 58 patients were prospectively recruited: 20 CHD-APAH, 20 CHD and 18 healthy controls. Exclusion criteria were pre-existing lung disease, significant smoking history, scoliosis and Down’s syndrome. Participants performed full lung function tests and provided serum and induced sputum samples at a single visit. Serum and sputum cytokines were measured by multiplex bead assay array and endothelin-1 levels measured by enzyme linked immunosorbent assay. Induced sputum was also assessed for total and differential cell counts. <h3>Results</h3> Serum cytokines and endothlin-1 levels were significantly elevated in patients with CHD-APAH in comparison to CHD and healthy controls (See Table 1). There were no significant differences in sputum cytokine or endothelin-1 levels between the 3 groups, with no differences in total or differential cell counts. A significant correlation between serum endothelin-1 levels and FEF25–75 was found for CHD-APAH patients (r = -0.6017, p = 0.0083 Spearman). There were no significant correlations between measures of airway obstruction and serum cytokine levels. <h3>Conclusions</h3> There is evidence of systemic inflammation in CHD-APAH patients but serum cytokines did not correlate with measures of airway dysfunction, and there was no evidence of airway inflammation. This suggests that inflammation does not play a role in airway obstruction in this patient group. Serum endothelin-1 is significantly elevated in CHD-APAH patients, and this did correlate with measures of airway obstruction. While elevated endothelin-1 in the pulmonary vessels may affect the adjacent airways, induced sputum endothelin-1 was not elevated. Whether serum endothelin-1 can cause bronchoconstriction without being associated with raised levels in the airways is unclear and requires further investigation.
A STUDY OF THE PHYSICAL ACTIVITY OF SUPPORTERS OF PROFESSIONAL SPORTS
Authors: R Dhand, G Rae, A Richardson
Journal: British Journal of Sports Medicine (2016)

Physical inactivity has been identified as the 4th leading cause of global mortality (http://www.who.int/topics/physical_activity/en). UK physical activity (PA) guidelines advise adults should achieve a weekly minimum of 150 minutes moderate activity, 75 minutes vigorous activity or a combination of the two. Adults should also partake in at least 2 days of muscle strengthening (MS) exercise per week (https://www.gov.uk/government/ publications/uk-physical-activity-guidelines). The project aimed to assess sports fans' knowledge of PA guidelines, to evaluate the amount of PA undertaken, and assess whether PA knowledge and participation is influenced by sport preference. A 2-part questionnaire (Part 1 knowledge of PA guidelines; Part 2 amount of PA) was completed by supporters aged over 18 attending a fixture at Durham CCC, Sunderland AFC, Newcastle Falcons RFC and Newcastle Racecourse. Supporters with health problems limiting moderate exercise were excluded from Part 2. 277 supporters were analysed. Relevant data for incomplete questionnaires was excluded and valid percentages were used. 72% of participants said they were aware of PA guidelines existing but only 6.2% correctly answered 150 minutes for the amount of PA advised per week. 25.6% correctly documented 2 MS days per week. 21.1% of participants failed to reach 150 minutes PA per week, with 59.6% undertaking MS exercise on less than 2 days per week. There was a significant difference between sports for number of days per week of MS exercise (mean (SD): Football 2.32 (2.01); Rugby 1.48 (1.63); Cricket 0.77 (1.37); Horse Racing 0.72 (1.29) [p&lt;0.001]). There was a significant difference between sports for participant perspective of how active they are [p=0.004]. Analysis shows that most sports fans do meet PA guidelines for moderate/vigorous activity. This is not the case for MS exercise, which may be influenced by preferred sport. Knowledge of recommended PA and MS exercise suggests further education is required.
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Authors: Jiangtao Ren, Xiaojun Liu, Chongyun Fang, Shuguang Jiang, Carl H. June, Yangbing Zhao
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Using gene-disrupted allogeneic T cells as universal effector cells provides an alternative and potentially improves current chimeric antigen receptor (CAR) T-cell therapy against cancers and infectious diseases. Experimental Design: The CRISPR/Cas9 system has recently emerged as a simple and efficient way for multiplex genome engineering. By combining lentiviral delivery of CAR and electro-transfer of Cas9 mRNA and gRNAs targeting endogenous TCR, β-2 microglobulin (B2M) and PD1 simultaneously, to generate gene-disrupted allogeneic CAR T cells deficient of TCR, HLA class I molecule and PD1. Results: The CRISPR gene–edited CAR T cells showed potent antitumor activities, both in vitro and in animal models and were as potent as non-gene–edited CAR T cells. In addition, the TCR and HLA class I double deficient T cells had reduced alloreactivity and did not cause graft-versus-host disease. Finally, simultaneous triple genome editing by adding the disruption of PD1 led to enhanced in vivo antitumor activity of the gene-disrupted CAR T cells. Conclusions: Gene-disrupted allogeneic CAR and TCR T cells could provide an alternative as a universal donor to autologous T cells, which carry difficulties and high production costs. Gene-disrupted CAR and TCR T cells with disabled checkpoint molecules may be potent effector cells against cancers and infectious diseases. Clin Cancer Res; 23(9); 2255–66. ©2016 AACR.
MLN9708, a Novel, Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma: Results of a Phase 1 Dose-Escalation Study
Authors: Sarit Assouline, Julie Chang, Robert Rifkin, Ai-Min Hui, Deborah Berg, Neeraj Gupta, Yingmei Xi, Alessandra Di Bacco, Peter Martin
Journal: Blood (2011)
Swedish Society for Physical Activity and Sports Medicine: a long history of excellence in sport and exercise medicine
Authors: Magnus Forssblad, Karim Khan
Journal: British Journal of Sports Medicine (2016)

Kudos to Sweden for its 11 medals at the Summer Olympic Games. From the comfort of the BJSM media centre in Vancouver, Sweden was first prominent via triple (and full set) swimming medalist, freestyle and butterfly swimmer Sarah Sjostrom. A big story in the middle of the Games was Sweden giving the US women's football team marching orders in a penalty shoot-out. No-one who saw it will forget Lisa Dahlkvist's ice-cool head (and smile) as she waited to take the match-winning penalty, while the opposing goalie delayed the moment of truth with some essential glove repair work. Whistle! BOOM! Goal!

And speaking of fearless, sangfroid, Sweden showed bike wizardry to medal on the road and in the mountain (Emma Johansson and Jenny Rissveds). BJSM commends all the SFAIM …
Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia
Authors: V S Tompkins, R Sompallae, T R Rosean, S Walsh, M Acevedo, A L Kovalchuk, S-S Han, X Jing, C Holman, J E Rehg, S Herms, J S Sunderland, H C Morse, S Janz
Journal: Blood Cancer Journal (2016)

Abstract Waldenström macroglobulinemia (WM) is a low-grade incurable immunoglobulin M + (IgM + ) lymphoplasmacytic lymphoma for which a genetically engineered mouse model of de novo tumor development is lacking. On the basis of evidence that the pro-inflammatory cytokine, interleukin 6 (IL6), and the survival-enhancing oncoprotein, B cell leukemia 2 (BCL2), have critical roles in the natural history of WM, we hypothesized that the enforced expression of IL6 and BCL2 in mice unable to perform immunoglobulin class switch recombination may result in a lymphoproliferative disease that mimics WM. To evaluate this possibility, we generated compound transgenic BALB/c mice that harbored the human BCL2 and IL6 transgenes, EμSV-BCL2-22 and H2-L d -hIL6, on the genetic background of activation-induced cytidine deaminase (AID) deficiency. We designated these mice BCL2 + IL6 + AID − and found that they developed—with full genetic penetrance (100% incidence) and suitably short latency (93 days median survival)—a severe IgM + lymphoproliferative disorder that recapitulated important features of human WM. However, the BCL2 + IL6 + AID − model also exhibited shortcomings, such as low serum IgM levels and histopathological changes not seen in patients with WM, collectively indicating that further refinements of the model are required to achieve better correlations with disease characteristics of WM.